25 XP   0   0   10

Cynata Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Cynata together

PenkeI guess you are interested in Cynata Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cynata Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cynata Therapeutics Ltd

I send you an email if I find something interesting about Cynata Therapeutics Ltd.

Quick analysis of Cynata (30 sec.)










What can you expect buying and holding a share of Cynata? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.09
Expected worth in 1 year
A$-0.07
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.16
Return On Investment
-84.7%

For what price can you sell your share?

Current Price per Share
A$0.19
Expected price per share
A$0.16 - A$0.23
How sure are you?
50%

1. Valuation of Cynata (5 min.)




Live pricePrice per Share (EOD)

A$0.19

Intrinsic Value Per Share

A$-1.06 - A$-0.57

Total Value Per Share

A$-0.96 - A$-0.48

2. Growth of Cynata (5 min.)




Is Cynata growing?

Current yearPrevious yearGrowGrow %
How rich?$10.9m$15.6m-$4.7m-43.2%

How much money is Cynata making?

Current yearPrevious yearGrowGrow %
Making money-$9.3m-$3.5m-$5.7m-61.9%
Net Profit Margin-863.0%-70.1%--

How much money comes from the company's main activities?

3. Financial Health of Cynata (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#680 / 1031

Most Revenue
#489 / 1031

Most Profit
#574 / 1031

Most Efficient
#812 / 1031

What can you expect buying and holding a share of Cynata? (5 min.)

Welcome investor! Cynata's management wants to use your money to grow the business. In return you get a share of Cynata.

What can you expect buying and holding a share of Cynata?

First you should know what it really means to hold a share of Cynata. And how you can make/lose money.

Speculation

The Price per Share of Cynata is A$0.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cynata.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cynata, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.09. Based on the TTM, the Book Value Change Per Share is A$-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cynata.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.05-27.3%-0.05-27.3%-0.02-10.4%-0.03-15.1%-0.02-11.5%
Usd Book Value Change Per Share-0.03-13.8%-0.03-13.8%-0.02-8.4%0.000.5%0.012.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-13.8%-0.03-13.8%-0.02-8.4%0.000.5%0.012.9%
Usd Price Per Share0.08-0.08-0.23-0.37-0.42-
Price to Earnings Ratio-1.57--1.57--11.88--16.35--23.92-
Price-to-Total Gains Ratio-3.11--3.11--14.65--8.35--33.54-
Price to Book Ratio1.34-1.34-2.70-6.83-9.08-
Price-to-Total Gains Ratio-3.11--3.11--14.65--8.35--33.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.123937
Number of shares8068
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.00
Usd Total Gains Per Share-0.030.00
Gains per Quarter (8068 shares)-211.727.89
Gains per Year (8068 shares)-846.8831.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-847-85703222
20-1694-170406354
30-2541-255109586
40-3388-33980126118
50-4234-42450158150
60-5081-50920189182
70-5928-59390221214
80-6775-67860252246
90-7622-76330284278
100-8469-84800316310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.016.01.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%8.09.00.047.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.017.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%8.09.00.047.1%

Fundamentals of Cynata

About Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Fundamental data was last updated by Penke on 2024-03-08 20:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cynata Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cynata earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Net Profit Margin of -863.0% means that $-8.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -863.0%. The company is making a huge loss. -2
  • The TTM is -863.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-863.0%TTM-863.0%0.0%
TTM-863.0%YOY-70.1%-793.0%
TTM-863.0%5Y-1,004.2%+141.1%
5Y-1,004.2%10Y-2,982.3%+1,978.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-863.0%-159.2%-703.8%
TTM-863.0%-202.3%-660.7%
YOY-70.1%-263.0%+192.9%
5Y-1,004.2%-452.4%-551.8%
10Y-2,982.3%-589.0%-2,393.3%
1.1.2. Return on Assets

Shows how efficient Cynata is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • -75.2% Return on Assets means that Cynata generated $-0.75 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cynata Therapeutics Ltd:

  • The MRQ is -75.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -75.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-75.2%TTM-75.2%0.0%
TTM-75.2%YOY-20.5%-54.7%
TTM-75.2%5Y-39.7%-35.5%
5Y-39.7%10Y-38.5%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-75.2%-12.5%-62.7%
TTM-75.2%-12.2%-63.0%
YOY-20.5%-11.2%-9.3%
5Y-39.7%-13.3%-26.4%
10Y-38.5%-14.6%-23.9%
1.1.3. Return on Equity

Shows how efficient Cynata is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • -85.3% Return on Equity means Cynata generated $-0.85 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cynata Therapeutics Ltd:

  • The MRQ is -85.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -85.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-85.3%TTM-85.3%0.0%
TTM-85.3%YOY-22.7%-62.6%
TTM-85.3%5Y-43.9%-41.4%
5Y-43.9%10Y-41.3%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-85.3%-16.0%-69.3%
TTM-85.3%-15.8%-69.5%
YOY-22.7%-13.9%-8.8%
5Y-43.9%-18.2%-25.7%
10Y-41.3%-19.1%-22.2%

1.2. Operating Efficiency of Cynata Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cynata is operating .

  • Measures how much profit Cynata makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • An Operating Margin of -1,000.0% means the company generated $-10.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -1,000.0%. The company is operating very inefficient. -2
  • The TTM is -1,000.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,000.0%TTM-1,000.0%0.0%
TTM-1,000.0%YOY-178.1%-821.9%
TTM-1,000.0%5Y-1,417.5%+417.5%
5Y-1,417.5%10Y-3,633.5%+2,216.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,000.0%-299.5%-700.5%
TTM-1,000.0%-208.5%-791.5%
YOY-178.1%-280.2%+102.1%
5Y-1,417.5%-459.9%-957.6%
10Y-3,633.5%-596.9%-3,036.6%
1.2.2. Operating Ratio

Measures how efficient Cynata is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 10.17 means that the operating costs are $10.17 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 10.169. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.169. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ10.169TTM10.1690.000
TTM10.169YOY1.817+8.352
TTM10.1695Y14.260-4.091
5Y14.26010Y36.378-22.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.1692.817+7.352
TTM10.1693.181+6.988
YOY1.8173.609-1.792
5Y14.2605.554+8.706
10Y36.3787.396+28.982

1.3. Liquidity of Cynata Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cynata is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.46 means the company has $7.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 7.460. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.460. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.460TTM7.4600.000
TTM7.460YOY9.326-1.866
TTM7.4605Y11.927-4.467
5Y11.92710Y19.861-7.934
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4603.987+3.473
TTM7.4604.440+3.020
YOY9.3265.569+3.757
5Y11.9276.158+5.769
10Y19.8616.492+13.369
1.3.2. Quick Ratio

Measures if Cynata is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Quick Ratio of 7.33 means the company can pay off $7.33 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 7.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.326TTM7.3260.000
TTM7.326YOY9.244-1.918
TTM7.3265Y11.755-4.428
5Y11.75510Y19.729-7.974
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3263.653+3.673
TTM7.3264.158+3.168
YOY9.2445.515+3.729
5Y11.7556.012+5.743
10Y19.7296.206+13.523

1.4. Solvency of Cynata Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cynata assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cynata to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Cynata assets are financed with 11.9% credit (debt) and the remaining percentage (100% - 11.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.119. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.119. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.1190.000
TTM0.119YOY0.097+0.022
TTM0.1195Y0.083+0.036
5Y0.08310Y0.059+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.336-0.217
TTM0.1190.330-0.211
YOY0.0970.267-0.170
5Y0.0830.367-0.284
10Y0.0590.378-0.319
1.4.2. Debt to Equity Ratio

Measures if Cynata is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.5% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.135. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.135. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.1350.000
TTM0.135YOY0.108+0.027
TTM0.1355Y0.091+0.044
5Y0.09110Y0.064+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1350.376-0.241
TTM0.1350.398-0.263
YOY0.1080.334-0.226
5Y0.0910.431-0.340
10Y0.0640.476-0.412

2. Market Valuation of Cynata Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cynata generates.

  • Above 15 is considered overpriced but always compare Cynata to the Biotechnology industry mean.
  • A PE ratio of -1.57 means the investor is paying $-1.57 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -2.390. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.573. Based on the earnings, the company is expensive. -2
  • The TTM is -1.573. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.390MRQ-1.573-0.818
MRQ-1.573TTM-1.5730.000
TTM-1.573YOY-11.876+10.303
TTM-1.5735Y-16.351+14.778
5Y-16.35110Y-23.919+7.568
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.390-2.697+0.307
MRQ-1.573-2.422+0.849
TTM-1.573-2.709+1.136
YOY-11.876-4.116-7.760
5Y-16.351-6.257-10.094
10Y-23.919-6.478-17.441
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -2.390. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.572. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.572. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.390MRQ-1.572-0.817
MRQ-1.572TTM-1.5720.000
TTM-1.572YOY-19.606+18.034
TTM-1.5725Y-20.836+19.264
5Y-20.83610Y-30.710+9.874
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.390-3.344+0.954
MRQ-1.572-2.939+1.367
TTM-1.572-3.486+1.914
YOY-19.606-5.592-14.014
5Y-20.836-8.464-12.372
10Y-30.710-8.872-21.838
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cynata is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.34 means the investor is paying $1.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is 2.040. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.342. Based on the equity, the company is underpriced. +1
  • The TTM is 1.342. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.040MRQ1.342+0.698
MRQ1.342TTM1.3420.000
TTM1.342YOY2.699-1.357
TTM1.3425Y6.830-5.488
5Y6.83010Y9.076-2.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0402.198-0.158
MRQ1.3422.042-0.700
TTM1.3422.121-0.779
YOY2.6992.907-0.208
5Y6.8303.682+3.148
10Y9.0764.114+4.962
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cynata Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cynata Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.040-0.0400%-0.025-39%0.001-2783%0.008-579%
Book Value Per Share--0.0930.0930%0.133-30%0.108-14%0.085+9%
Current Ratio--7.4607.4600%9.326-20%11.927-37%19.861-62%
Debt To Asset Ratio--0.1190.1190%0.097+22%0.083+44%0.059+103%
Debt To Equity Ratio--0.1350.1350%0.108+25%0.091+48%0.064+112%
Dividend Per Share----0%-0%-0%-0%
Eps---0.079-0.0790%-0.030-62%-0.044-45%-0.034-58%
Free Cash Flow Per Share---0.080-0.0800%-0.018-77%-0.037-54%-0.028-65%
Free Cash Flow To Equity Per Share---0.042-0.0420%-0.017-59%0.004-1086%0.008-603%
Gross Profit Margin--1.0041.0040%1.012-1%1.053-5%1.027-2%
Intrinsic Value_10Y_max---0.574--------
Intrinsic Value_10Y_min---1.058--------
Intrinsic Value_1Y_max---0.034--------
Intrinsic Value_1Y_min---0.059--------
Intrinsic Value_3Y_max---0.121--------
Intrinsic Value_3Y_min---0.219--------
Intrinsic Value_5Y_max---0.228--------
Intrinsic Value_5Y_min---0.423--------
Market Cap34130080.000+34%22454000.00022454000.0000%64667520.000-65%102210608.000-78%115952456.000-81%
Net Profit Margin---8.630-8.6300%-0.701-92%-10.042+16%-29.823+246%
Operating Margin---10.000-10.0000%-1.781-82%-14.175+42%-36.335+263%
Operating Ratio--10.16910.1690%1.817+460%14.260-29%36.378-72%
Pb Ratio2.040+34%1.3421.3420%2.699-50%6.830-80%9.076-85%
Pe Ratio-2.390-52%-1.573-1.5730%-11.876+655%-16.351+940%-23.919+1421%
Price Per Share0.190+34%0.1250.1250%0.360-65%0.569-78%0.646-81%
Price To Free Cash Flow Ratio-2.390-52%-1.572-1.5720%-19.606+1147%-20.836+1225%-30.710+1853%
Price To Total Gains Ratio-4.723-52%-3.107-3.1070%-14.654+372%-8.350+169%-33.540+979%
Quick Ratio--7.3267.3260%9.244-21%11.755-38%19.729-63%
Return On Assets---0.752-0.7520%-0.205-73%-0.397-47%-0.385-49%
Return On Equity---0.853-0.8530%-0.227-73%-0.439-49%-0.413-52%
Total Gains Per Share---0.040-0.0400%-0.025-39%0.001-2783%0.008-579%
Usd Book Value--10915249.65610915249.6560%15629163.446-30%12632349.043-14%9997702.689+9%
Usd Book Value Change Per Share---0.026-0.0260%-0.016-39%0.001-2783%0.005-579%
Usd Book Value Per Share--0.0610.0610%0.087-30%0.070-14%0.056+9%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.052-0.0520%-0.020-62%-0.029-45%-0.022-58%
Usd Free Cash Flow---9316624.127-9316624.1270%-2151501.311-77%-4290950.076-54%-3247372.682-65%
Usd Free Cash Flow Per Share---0.052-0.0520%-0.012-77%-0.024-54%-0.018-65%
Usd Free Cash Flow To Equity Per Share---0.027-0.0270%-0.011-59%0.003-1086%0.005-603%
Usd Market Cap22263051.184+34%14646744.20014646744.2000%42182623.296-65%66671979.598-78%75635787.049-81%
Usd Price Per Share0.124+34%0.0820.0820%0.235-65%0.371-78%0.421-81%
Usd Profit---9313209.989-9313209.9890%-3551885.696-62%-4948949.482-47%-3831968.508-59%
Usd Revenue--1079106.4131079106.4130%5068648.228-79%2371354.460-54%1231043.521-12%
Usd Total Gains Per Share---0.026-0.0260%-0.016-39%0.001-2783%0.005-579%
 EOD+5 -3MRQTTM+0 -0YOY+3 -315Y+6 -2810Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of Cynata Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.390
Price to Book Ratio (EOD)Between0-12.040
Net Profit Margin (MRQ)Greater than0-8.630
Operating Margin (MRQ)Greater than0-10.000
Quick Ratio (MRQ)Greater than17.326
Current Ratio (MRQ)Greater than17.460
Debt to Asset Ratio (MRQ)Less than10.119
Debt to Equity Ratio (MRQ)Less than10.135
Return on Equity (MRQ)Greater than0.15-0.853
Return on Assets (MRQ)Greater than0.05-0.752
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cynata Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.625
Ma 20Greater thanMa 500.182
Ma 50Greater thanMa 1000.172
Ma 100Greater thanMa 2000.148
OpenGreater thanClose0.185
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets18,994
Total Liabilities2,260
Total Stockholder Equity16,733
 As reported
Total Liabilities 2,260
Total Stockholder Equity+ 16,733
Total Assets = 18,994

Assets

Total Assets18,994
Total Current Assets16,861
Long-term Assets2,133
Total Current Assets
Cash And Cash Equivalents 16,167
Short-term Investments 26
Net Receivables 367
Other Current Assets 327
Total Current Assets  (as reported)16,861
Total Current Assets  (calculated)16,887
+/- 26
Long-term Assets
Intangible Assets 2,133
Long-term Assets  (as reported)2,133
Long-term Assets  (calculated)2,133
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,260
Long-term Liabilities0
Total Stockholder Equity16,733
Total Current Liabilities
Accounts payable 1,309
Other Current Liabilities 952
Total Current Liabilities  (as reported)2,260
Total Current Liabilities  (calculated)2,260
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock81,625
Retained Earnings -72,574
Accumulated Other Comprehensive Income 7,683
Total Stockholder Equity (as reported)16,733
Total Stockholder Equity (calculated)16,733
+/-0
Other
Capital Stock81,625
Cash and Short Term Investments 16,167
Common Stock Shares Outstanding 145,092
Liabilities and Stockholders Equity 18,994
Net Debt -16,167
Net Invested Capital 16,733
Net Tangible Assets 16,733
Net Working Capital 14,601



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-30
> Total Assets 
3,557
2,328
1,420
1,249
1,218
1,017
1,793
9,926
9,125
9,031
14,254
16,133
12,250
17,481
29,975
26,548
18,994
18,99426,54829,97517,48112,25016,13314,2549,0319,1259,9261,7931,0171,2181,2491,4202,3283,557
   > Total Current Assets 
3,489
2,181
1,224
972
1,207
1,017
1,150
5,104
4,751
4,937
10,441
12,600
7,330
13,851
27,282
24,135
16,861
16,86124,13527,28213,8517,33012,60010,4414,9374,7515,1041,1501,0171,2079721,2242,1813,489
       Cash And Cash Equivalents 
3,248
2,079
1,005
628
389
993
1,117
5,095
4,704
4,879
10,350
12,206
6,977
13,650
26,717
23,798
16,167
16,16723,79826,71713,6506,97712,20610,3504,8794,7045,0951,1179933896281,0052,0793,248
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
4
4
26
26
26
26262644000000000000
       Net Receivables 
133
102
219
344
510
24
33
10
48
58
91
56
67
17
278
100
367
367100278176756915848103324510344219102133
       Inventory 
106
0
0
0
308
0
0
0
0
0
0
0
0
0
0
0
0
000000000000308000106
       Other Current Assets 
2
2
83
161
421
0
14
4
4
4
4
338
286
184
287
237
327
32723728718428633844441404211618322
   > Long-term Assets 
68
146
196
277
11
0
643
4,822
4,374
4,093
3,813
3,533
4,919
3,630
2,693
2,413
2,133
2,1332,4132,6933,6304,9193,5333,8134,0934,3744,82264301127719614668
       Property Plant Equipment 
9
7
2
20
11
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001120279
       Goodwill 
0
0
0
0
0
0
0
4,822
0
0
0
0
0
0
0
0
0
0000000004,8220000000
       Intangible Assets 
58
139
194
256
0
0
0
4,822
4,374
4,093
3,813
3,533
3,253
2,972
2,693
2,413
2,133
2,1332,4132,6932,9723,2533,5333,8134,0934,3744,82200025619413958
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
4,093
3,813
3,533
1,666
658
0
0
0
0006581,6663,5333,8134,093000000000
> Total Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
2,2602,5881,6026901,27874639044737571150163246317458117147
   > Total Current Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
2,2602,5881,6026901,27874639044737571150163246317458117147
       Short-term Debt 
0
0
0
0
20
0
0
0
33
0
0
0
0
0
0
0
0
0000000033000200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
33
0
0
0
0
0
0
0
0
000000003300000000
       Accounts payable 
63
20
10
60
134
17
14
35
153
134
95
299
791
297
676
1,580
1,309
1,3091,5806762977912999513415335141713460102063
       Other Current Liabilities 
38
96
449
257
92
146
136
36
190
314
295
447
487
392
926
1,007
952
9521,00792639248744729531419036136146922574499638
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
791
297
676
1,580
0
01,580676297791000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
3,533
3,253
2,972
2,693
2,413
2,133
2,1332,4132,6932,9723,2533,53300000000000
> Total Stockholder Equity
3,410
2,211
962
932
972
854
1,643
9,855
8,750
8,583
13,865
15,387
10,971
16,791
28,373
23,960
16,733
16,73323,96028,37316,79110,97115,38713,8658,5838,7509,8551,6438549729329622,2113,410
   Common Stock
5,043
5,313
5,514
6,968
9,485
10,914
12,338
22,282
24,460
28,792
38,378
44,192
47,988
57,165
74,900
74,900
81,625
81,62574,90074,90057,16547,98844,19238,37828,79224,46022,28212,33810,9149,4856,9685,5145,3135,043
   Retained Earnings -72,574-58,296-52,851-45,161-41,522-33,050-28,484-23,931-18,991-15,279-12,239-11,324-9,781-7,216-5,100-3,650-1,815
   Accumulated Other Comprehensive Income 
182
548
548
1,180
1,268
1,264
1,544
2,852
3,281
3,722
3,971
4,245
4,506
4,787
6,324
7,356
7,683
7,6837,3566,3244,7874,5064,2453,9713,7223,2812,8521,5441,2641,2681,180548548182
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue1,654
Cost of Revenue-280
Gross Profit1,3741,374
 
Operating Income (+$)
Gross Profit1,374
Operating Expense-16,543
Operating Income-14,888-15,168
 
Operating Expense (+$)
Research Development12,394
Selling General Administrative3,176
Selling And Marketing Expenses56
Operating Expense16,54315,626
 
Net Interest Income (+$)
Interest Income258
Interest Expense-0
Other Finance Cost-95
Net Interest Income353
 
Pretax Income (+$)
Operating Income-14,888
Net Interest Income353
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-14,277-16,800
EBIT - interestExpense = -16,543
-14,630
-14,277
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-16,543-14,277
Earnings Before Interest and Taxes (EBITDA)-16,263
 
After tax Income (+$)
Income Before Tax-14,277
Tax Provision-0
Net Income From Continuing Ops-14,277-14,277
Net Income-14,277
Net Income Applicable To Common Shares-14,278
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,285
Total Other Income/Expenses Net1,912-353
 

Technical Analysis of Cynata
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cynata. The general trend of Cynata is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cynata's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cynata Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.21 < 0.23 < 0.23.

The bearish price targets are: 0.16 > 0.16 > 0.16.

Tweet this
Cynata Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cynata Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cynata Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cynata Therapeutics Ltd. The current macd is 0.00191941.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cynata price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cynata. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cynata price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cynata Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartCynata Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cynata Therapeutics Ltd. The current adx is 14.48.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cynata shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cynata Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cynata Therapeutics Ltd. The current sar is 0.155.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cynata Therapeutics Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cynata Therapeutics Ltd. The current rsi is 53.63. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cynata Therapeutics Ltd Daily Relative Strength Index (RSI) ChartCynata Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cynata Therapeutics Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cynata price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cynata Therapeutics Ltd Daily Stochastic Oscillator ChartCynata Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cynata Therapeutics Ltd. The current cci is 56.18.

Cynata Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartCynata Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cynata Therapeutics Ltd. The current cmo is 9.01339551.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cynata Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartCynata Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cynata Therapeutics Ltd. The current willr is -12.5.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cynata Therapeutics Ltd Daily Williams %R ChartCynata Therapeutics Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cynata Therapeutics Ltd. The current atr is 0.01521106.

Cynata Therapeutics Ltd Daily Average True Range (ATR) ChartCynata Therapeutics Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cynata Therapeutics Ltd. The current obv is -7,622,260.

Cynata Therapeutics Ltd Daily On-Balance Volume (OBV) ChartCynata Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cynata Therapeutics Ltd. The current mfi is 40.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cynata Therapeutics Ltd Daily Money Flow Index (MFI) ChartCynata Therapeutics Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cynata Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Cynata Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cynata Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.625
Ma 20Greater thanMa 500.182
Ma 50Greater thanMa 1000.172
Ma 100Greater thanMa 2000.148
OpenGreater thanClose0.185
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cynata with someone you think should read this too:
  • Are you bullish or bearish on Cynata? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cynata? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cynata Therapeutics Ltd

I send you an email if I find something interesting about Cynata Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Cynata Therapeutics Ltd.

Receive notifications about Cynata Therapeutics Ltd in your mailbox!